Funding Round

Boltz bets drug discovery is sold by token

Boltz raised $110M to sell molecular models by usage, with token demand up 50-fold in four months.

StartupHub.ai Staff

By StartupHub.ai Staff, reviewed by Daniel Singer, Editor

2 min read

Boltz molecular AI models for drug discovery
Credit: a16z Blog

Boltz closed a $110M Series A to sell frontier molecular intelligence as a reagent, a16z investors Jorge Conde and Zak Doric said.

I think they are betting that usage beats ownership in drug discovery. Weekly molecular token consumption rose roughly 50-fold in just the last four months after BoltzMol-1 and BoltzProt-1, the firm said.

That is a real signal.

By the time a16z co-led the seed round last year, Boltz open source models had already reached every top 20 pharmaceutical company, the investors said. Commercial models are now deployed at Pfizer, GSK, Takeda, BMS and other leading companies, with founders Gabriele Corso, Jeremy Wohlwend and Saro Passaro adding Boltz Lab for biologists and chemists plus an API that works inside existing workflows and agents such as Claude Code and Codex.

The model is molecular tokens, units of molecular information processed per task. A quick prediction costs little, the firm said, while a full design campaign to generate and refine molecules against multiple objectives can consume far more, much as labs already budget for sequencing reads or assay reagents.

Data still decides quality. Boltz PBC partnered with Excelra to train BoltzMol-1 ADMET models on curated GOSTAR data for solubility, lipophilicity and permeability screening, according to a November 10 announcement. That tells you where near term differentiation comes from, not just architecture but clean pharmacology data that teaches models which compounds to reject.

The fair pushback is that billions have gone to proprietary AI pipelines for a reason. A captive program can keep data, feedback and upside in one place, and frontier labs are chasing the same prize with far larger compute budgets.

That risk does not kill the claim. Proprietary pipelines need one big win, while Boltz can grow if thousands of teams run millions of smaller predictions and screens, and early pharma adoption plus token growth suggest scientists will pay to explore computationally before they commit to synthesis. If you are a founder here, sell compute that earns its next experiment.

Sources

Get the free daily brief every morning

Every morning the day's AI news, new AI startups and new funding rounds. Free and takes a few minutes to read, unsubscribe at any time.

Join 64,000 other subscribers.

TopicsBoltzBoltzMol-1BoltzProt-1Andreessen HorowitzPfizerGSKTakedaBMS

StartupHub.ai StaffDaniel SingerWritten by StartupHub.ai Staff, Editorial teamReviewed by Daniel Singer, EditorAbout

StartupHub.ai Staff, Editorial team

The staff writers of StartupHub.ai, ranging from investment analysts to avid AI tool users, early adopters and critical enthusiasts. Backgrounds span engineering, business and the arts. We hold every piece to rigorous standards of research and review.

Daniel Singer, Editor

Daniel Singer is an AI expert who has been writing about, covering and building AI technology since 2018.

More from Daniel Singer

Test your Agent Readiness now

Paste your website. How well ChatGPT, Claude and the other agents can read and use a site, in about a minute.

Watch

The videos behind the news, one flip at a time

The feed mixes the videos from our articles with startup demos and you flip through them like TV channels for free with no signup.